A feasible molecular diagnostic strategy for rare genetic disorders within resource-constrained environments

• Published in: Journal of community genetics Vol. 15; no. 1; pp. 39 - 48
• Main Authors: Mudau, Maria Mabyalwa, Seymour, Heather, Nevondwe, Patracia, Kerr, Robyn, Spencer, Careni, Feben, Candice, Lombard, Zané, Honey, Engela, Krause, Amanda, Carstens, Nadia
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-02-2024; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Biomedicine; CHARGE syndrome; Diagnosis; Dysostosis; Epidemiology; Gene Function; Gene Therapy; Genetic disorders; Human Genetics; Next-generation sequencing; Patients; Phenotypes; Public Health; Rare diseases; Custom-designed NGS targeted panel; Genetic testing; Resource-constrained environment
• ISSN: 1868-310X; 1868-6001; 1868-6001
• DOI: 10.1007/s12687-023-00674-8

Timely and accurate diagnosis of rare genetic disorders is critical, as it enables improved patient management and prognosis. In a resource-constrained environment such as the South African State healthcare system, the challenge is to design appropriate and cost-effective assays that will enable accurate genetic diagnostic services in patients of African ancestry across a broad disease spectrum. Next-generation sequencing (NGS) has transformed testing approaches for many Mendelian disorders, but this technology is still relatively new in our setting and requires cost-effective ways to implement. As a proof of concept, we describe a feasible diagnostic strategy for genetic disorders frequently seen in our genetics clinics (RASopathies, Cornelia de Lange syndrome, Treacher Collins syndrome, and CHARGE syndrome). The custom-designed targeted NGS gene panel enabled concurrent variant screening for these disorders. Samples were batched during sequencing and analyzed selectively based on the clinical phenotype. The strategy employed in the current study was cost-effective, with sequencing and analysis done at USD849.68 per sample and achieving an overall detection rate of 54.5%. The strategy employed is cost-effective as it allows batching of samples from patients with different diseases in a single run, an approach that can be utilized with rare and less frequently ordered molecular diagnostic tests. The subsequent selective analysis pipeline allowed for timeous reporting back of patients results. This is feasible with a reasonable yield and can be employed for the molecular diagnosis of a wide range of rare monogenic disorders in a resource-constrained environment.